Hydroxychloroquine in Stage 1 Type 1 Diabetes.

Area of Science:

• Immunology
• Endocrinology
• Clinical Trials

Background:

• Innate immune responses are implicated in the early stages of type 1 diabetes (T1D).
• Understanding modulators of early T1D progression is crucial for intervention strategies.

Purpose of the Study:

• To investigate if blocking innate immune cells with hydroxychloroquine could delay or prevent the progression of stage 1 T1D to stage 2.
• To assess the safety and efficacy of hydroxychloroquine in individuals with early-stage T1D.

Main Methods:

• A randomized controlled trial involving 273 individuals with stage 1 T1D.
• Participants were assigned to receive either hydroxychloroquine (5 mg/kg/day, max 400 mg) or a placebo.
• Progression to stage 2 T1D (defined by multiple autoantibodies and impaired glucose tolerance) was the primary endpoint.

Main Results:

• The trial was stopped early due to futility; hydroxychloroquine did not delay progression to stage 2 T1D.
• No safety concerns were reported with hydroxychloroquine treatment.
• Secondary analyses indicated a transient decrease in glucose AUC and reduced titers of anti-GAD and anti-insulin autoantibodies in the hydroxychloroquine group.

Conclusions:

• Hydroxychloroquine is ineffective in delaying the progression of type 1 diabetes from stage 1 to stage 2.
• Hydroxychloroquine treatment demonstrated a beneficial effect on reducing autoantibody acquisition and titers in early T1D.